Dr Magdalene Montgomery
University of Melbourne
About the talk: Diabetes is predicted to be the 4th leading cause of death by 2030. 70% of individuals with type 2 diabetes (T2D) have non-alcoholic fatty liver disease (NAFLD) and thereby an increased risk for developing advanced liver disease, including non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and liver cancer. Despite this increasing clinical epidemic, there are currently no approved pharmacotherapies for NASH and liver fibrosis. Furthermore, existing diabetes therapies have limited efficacy, limited tolerability and significant mechanism-based side effects, and newer approaches are urgently needed. In response to these unmet needs, our team developed the world-first human discovery platform to assess liver-secreted proteins (known as ‘hepatokines’) in patients with progressive NAFLD. We identify arylsulfatase A (ARSA) as a novel hepatokine that is upregulated in NASH and type 2 diabetes, and that is a novel therapeutic target for metabolic disease.
About the speaker: Dr Magda Montgomery is a NHMRC Career Development Fellow, Head of the Metabolic Crosstalk Laboratory and Theme Lead of the Metabolism and Cardiovascular Sciences Program in the Department of Anatomy and Physiology, University of Melbourne. Dr Montgomery received her PhD at the University of Wollongong in 2011, and her postdoctoral training in the areas of obesity, type 2 diabetes and endocrine physiology at the Garvan Institute of Medical Research(2011 – 2013), the University of New South Wales (2013 – 2016), and at Monash University (2016 – 2018). In 2018, Dr Montgomery moved to the University of Melbourne, where she currently investigates links between the development of obesity, type 2 diabetes and liver disease, with a special focus on understanding perturbations in the endocrine function of the liver.
Read more about Dr Magdalene Montgomery work here.
Register to attend using the link below.